Platelet-rich plasma (PRP) for knee disorders

Shahid, Mohammad; Kundra, Rik

doi:10.1302/2058-5241.2.160004

Cited by 61 publications

(48 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[392,393] Adverse events with PRP treatment were not significantly increased in comparison with other knee OA treatments consistent with earlier studies using PRP as an intervention in knee OA. [393][394][395] HA hydrogel n/a Dexamethasone Cortocosteroid [310] Adant (Suprahyal) 500-1000 Tenoxicam NSAID [311] Variofill (Adoderm, Langenfeld, Gmbh) HMWCR Diclofenac Sodium clodronate Triamcinolone acetonide Ropivacaine HCl NSAID DMOAD Cortocosteroid Anaesthetic [312] [ 313] Hydros, Hydros-TA HMW Triamcinolone acetonide Cortocosteroid [314] Cingal 1900 Triamcinolone acetonide Cortocosteroid [315] Hylan GF-20 HMWCR Triamcinolone acetonide Cortocosteroid [316] HA solution 800 Mannitol Anti-oxidant [317] Go-on matrix Go- Ostenil Plus 1500 Mannitol Anti-oxidant [320] Happyvix 1500 Mannitol Anti-oxidant [320] Happycross 1500 Mannitol Anti-oxidant [320] Synolis V-A 2000 Sorbitol Anti-oxidant [320] HA 4AR conjugate 2200 4 aminoresorcinol Anti-oxidant [321] Ostenil 1000-2000 l-glutathione Anti-oxidant [322] Arthrum HCS 2800 CS GAG [320] Surgical Syonium 2800 CS GAG [320] HA-sCT conjugate 200 Salmon calcitonin DMOAD [323] HA ADAMTS inhibitor n/a ADAMTS inhibitor DMOAD [324] HA hydrogel 60-120 Doxycycline DMOAD [296] Hanox [325] n/a, not available; HMW, high molecular weight; HMWCR, high molecular weight cross-linked.…”

Section: Therapeutic Properties Of Platelet Rich Plasmasupporting

confidence: 81%

“…[391] A systematic review, which included data from six randomized controlled trials comparing the effectiveness of PRP with other intra-articular injections, exercise, or analgesia for a minimum of 6 months PRP produced statistically significant improvements in WOMAC scores for up to 12 months. [393][394][395] www.advancedsciencenews.com www.advtherap.com HA hydrogel n/a Dexamethasone Cortocosteroid [310] Adant (Suprahyal) 500-1000 Tenoxicam NSAID [311] Variofill (Adoderm, Langenfeld, Gmbh) HMWCR Diclofenac Sodium clodronate Triamcinolone acetonide Ropivacaine HCl NSAID DMOAD Cortocosteroid Anaesthetic [312] [ 313] Hydros, Hydros-TA HMW Triamcinolone acetonide Cortocosteroid [314] Cingal 1900 Triamcinolone acetonide Cortocosteroid [315] Hylan GF-20 HMWCR Triamcinolone acetonide Cortocosteroid [316] HA solution 800 Mannitol Anti-oxidant [317] Go-on matrix Ostenil Plus 1500 Mannitol Anti-oxidant [320] Happyvix 1500 Mannitol Anti-oxidant [320] Happycross 1500 Mannitol Anti-oxidant [320] Synolis V-A 2000 Sorbitol Anti-oxidant [320] HA 4AR conjugate 2200 4 aminoresorcinol Anti-oxidant [321] Ostenil 1000-2000 l-glutathione Anti-oxidant [322] Arthrum HCS 2800 CS GAG [320] Surgical Syonium 2800 CS GAG [320] HA-sCT conjugate 200 Salmon calcitonin DMOAD [323] HA ADAMTS inhibitor n/a ADAMTS inhibitor DMOAD [324] HA hydrogel 60-120 Doxycycline DMOAD [296] Hanox Hanox M-XL 1500 n/a Cortivazol Triamcinolone hexacetonide Mannitol + lidocaine clorhydrate Cortocosteroid Cortocosteroid Anti-oxidant + local anaesthetic [325] n/a, not available; HMW, high molecular weight; HMWCR, high molecular weight cross-linked. [393][394][395] www.advancedsciencenews.com www.advtherap.com HA hydrogel n/a Dexamethasone Cortocosteroid [310] Adant (Suprahyal) 500-1000 Tenoxicam NSAID [311] Variofill (Adoderm, Langenfeld, Gmbh) HMWCR Diclofenac Sodium clodronate Triamcinolone acetonide Ropivacaine HCl NSAID DMOAD Cortocosteroid Anaesthetic …”

Section: Therapeutic Properties Of Platelet Rich Plasmamentioning

confidence: 99%

See 1 more Smart Citation

Glycosaminoglycan and Proteoglycan Biotherapeutics in Articular Cartilage Protection and Repair Strategies: Novel Approaches to Visco‐supplementation in Orthobiologics

Hayes

Melrose

2019

Advanced Therapeutics

View full text Add to dashboard Cite

The aim of this study is to review developments in glycosaminoglycan and proteoglycan research relevant to cartilage repair biology and in particular the treatment of osteoarthritis (OA). Glycosaminoglycans decorate a diverse range of extracellular matrix and cell associated proteoglycans conveying structural organization and physico-chemical properties to tissues. They play key roles mediating cellular interactions with bioactive growth factors, cytokines, and morphogenetic proteins, and structural fibrillar collagens, cell interactive and extracellular matrix proteoglycans, and glycoproteins which define tissue function. Proteoglycan degradation detrimentally affects tissue functional properties. Therapeutic strategies have been developed to counter these degenerative changes. Neo-proteoglycans prepared from chondroitin sulfate or hyaluronan and hyaluronan or collagen-binding peptides emulate the interactive, water imbibing, weight bearing, and surface lubricative properties of native proteoglycans. Many neo-proteoglycans outperform native proteoglycans in terms of water imbibition, matrix stabilization, and resistance to proteolytic degradation. The biospecificity of recombinant proteoglycans however, provides precise attachment to native target molecules. Visco-supplements augmented with growth factors/therapeutic cells, hyaluronan, and lubricin (orthobiologicals) have the capacity to lubricate and protect cartilage, control inflammation, and promote cartilage repair and regeneration of early cartilage lesions and may represent a more effective therapeutic approach to the treatment of mild to moderate OA and deserve further study.Similar protective perineural net structures assembled from the lectican proteoglycan family and HA also occur in the CNS/PNS. These so called perineuronal nets are visualized by immunolocalization of MAb 1B5 (+) epitope in rat brain (e) and pericellular 1B5(+) epitope expression by isolated neurons (f). Scale bars 100 µm.

show abstract

Section: Therapeutic Properties Of Platelet Rich Plasmasupporting

confidence: 81%

Section: Therapeutic Properties Of Platelet Rich Plasmamentioning

confidence: 99%

Glycosaminoglycan and Proteoglycan Biotherapeutics in Articular Cartilage Protection and Repair Strategies: Novel Approaches to Visco‐supplementation in Orthobiologics

Hayes

Melrose

2019

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…Aiming to stop and revert the degeneration associated with OA, IA injections of autologous conditioned serum (ACS), platelet rich plasma (PRP), and mesenchymal stem cell (MSC) have been tested. 9 , 11 , 62 , 63 Their mechanisms of action is reduction of inflammatory reactions mediated by cytokines, and the induction of anabolism and chondrocyte differentiation via growth factors and stem cells contained in it. These methods are promising and some studies have reported them to be safe, well tolerated and, in some cases, superior to IA placebo and HA in terms of pain relief and knee function.…”

Section: Introductionmentioning

confidence: 99%

Knee osteoarthritis: pathophysiology and current treatment modalities

Mora¹,

Przkora²,

Cruz-Almeida³

2018

JPR

392

294

View full text Add to dashboard Cite

For decades, multiple attempts to fully understand knee osteoarthritis pathophysiology and natural history have been attempted. Despite the extensive amount of research regarding this topic, there are still marked controversies. This multifactorial condition gets influenced by local, systemic, and external factors and its progression and/or response to treatments widely varies from patient to patient. Multiple therapies have been studied in the past, low impact physical activity seems to be supported by all the current medical societies while other interventions have shown conflicting findings. Newer therapies and routes of administration are under investigation and some of them have shown promising preliminary reports. This review intends to give an overview of the current knowledge of pathophysiology and non-surgical therapies available for knee osteoarthritis.

show abstract

“…Además de las proteínas mencionadas, se usan otros productos biológicos no recombinantes; entre ellos, el ácido hialurónico y el plasma rico en plaquetas (PRP). Aunque parece ser mejor que la viscosuplementación intraarticular con ácido hialurónico (Paterson et al, 2016), la aplicación de PRP genera controversia debido a los resultados clínicos contradictorios y el beneficio sintomático transitorio reportado después de su aplicación (Shahid & Kundra, 2017). En estudio fase III se encuentra Ampion (albúmina sérica humana < 5kDa), producto biológico no recombinante para aplicación intraarticular que inhibe la secreción de citoquinas proinflamatorias sintetizadas por los linfocitos T (Bar-Or et al, 2014).…”

Section: Tratamientos De Las Lesiones Del Cartílago De La Rodillaunclassified

Terapias Celulares y Productos de Ingeniería de Tejidos para el Tratamiento de Lesiones Condrales de Rodilla

Cabrera

Duque²,

Fontanilla

2017

Rev. colomb. biotecnol.

View full text Add to dashboard Cite

RESUMENEl cartílago articular es un tejido vulnerable a las lesiones de diferente etiología; siendo uno de los más afectados, el cartílago de la rodilla. Aunque la mayoría de los tratamientos convencionales reducen los síntomas, generalmente conducen a la formación de fibrocartílago; el cual, posee características diferentes a las del cartílago hialino de las articulaciones. Son pocas las aproximaciones terapéuticas que promueven el reemplazo del tejido dañado por cartílago hialino funcional; las más exitosas son las denominadas terapias avanzadas, que aplican células y productos de ingeniería de tejidos con el fin de estimular la regeneración del cartílago. La mayoría de ellas se basan en colocar soportes hechos con biomateriales de diferente origen, que sembrados o no con células exógenas o endógenas, reemplazan al cartílago dañado y promueven su regeneración. Este trabajo revisa algunas de las aproximaciones terapéuticas enfocadas en la regeneración del cartílago articular de rodilla; así como, los biomateriales más empleados en la elaboración de soportes para terapia celular e ingeniería de tejido cartilaginoso.Palabras clave: biomaterial, cartílago, lesiones de rodilla, ingeniería de tejidos. ABSTRACTThe articular cartilage is prone to suffer lesions of different etiology, being the articular cartilage lesions of the knee the most common. Although most conventional treatments reduce symptoms they lead to the production of fibrocartilage, which has different characteristics than the hyaline cartilage of the joint. There are few therapeutic approaches that promote the replacement of damaged tissue by functional hyaline cartilage. Among them are the so-called advanced therapies, which use cells and tissue engineering products to promote cartilage regeneration. Most of them are based on scaffolds made of different biomaterials, which seeded or not with endogenous or exogenous cells, can be used as cartilage artificial replacement to improve joint function. This paper reviews some therapeutic approaches focused on the regeneration of articular cartilage of the knee and the biomaterials used to develop scaffolds for cell therapy and tissue engineering of cartilage. ARTÍCULO DE REVISIÓNRev.

show abstract

Platelet-rich plasma (PRP) for knee disorders

Cited by 61 publications

References 62 publications

Glycosaminoglycan and Proteoglycan Biotherapeutics in Articular Cartilage Protection and Repair Strategies: Novel Approaches to Visco‐supplementation in Orthobiologics

Glycosaminoglycan and Proteoglycan Biotherapeutics in Articular Cartilage Protection and Repair Strategies: Novel Approaches to Visco‐supplementation in Orthobiologics

Knee osteoarthritis: pathophysiology and current treatment modalities

Terapias Celulares y Productos de Ingeniería de Tejidos para el Tratamiento de Lesiones Condrales de Rodilla

Contact Info

Product

Resources

About